Adelbert Wadsworth, PA
Medical · Las Vegas, NVNPI 1699053660
Payments from drug & device makers
Across 449 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$2K
- Teleflex LLC$1K
- Sumitomo Pharma America, Inc.$1K
- Dendreon Pharmaceuticals LLC$879
- Johnson & Johnson$648
- Antares Pharma, Inc.$517
- plus $5K from 30 others
What the payments were for
- Travel & lodging$4514%
- Food & beverage$9,43789%
- Education$7387%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 56 | $1,520 |
| Teleflex LLC | 28 | $1,347 |
| Sumitomo Pharma America, Inc. | 55 | $1,115 |
| Dendreon Pharmaceuticals LLC | 31 | $879 |
| Johnson & Johnson | 31 | $648 |
| Antares Pharma, Inc. | 45 | $517 |
| Boston Scientific | 6 | $492 |
| Procept Biorobotics Corporation | 7 | $443 |
| Urogen Pharma, Inc. | 20 | $424 |
| AbbVie | 20 | $401 |
| Urovant Sciences Inc | 19 | $348 |
| Coloplast | 26 | $321 |
| Pfizer | 13 | $245 |
| Myriad Genetic Laboratories, Inc. | 8 | $233 |
| Endo Pharmaceuticals Inc. | 11 | $188 |
| Accord Healthcare, Inc. | 9 | $177 |
| Bayer | 10 | $175 |
| Blue Earth Diagnostics | 7 | $142 |
| Axonics, Inc. | 1 | $138 |
| Myovant Sciences Inc. | 6 | $124 |
| 180 Medical, Inc. | 8 | $122 |
| Endo USA, Inc. | 5 | $91 |
| Merck | 4 | $87 |
| Novartis | 3 | $83 |
| Progenics Pharmaceuticals, Inc. | 2 | $49 |
| Halozyme Inc | 3 | $47 |
| Rochester Medical Corporation | 3 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Hollister Incorporated | 2 | $38 |
| Amgen | 2 | $33 |
| Tolmar, Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Palette Life Sciences, Inc. | 1 | $17 |
| Immunitybio, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,626 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 16 | $213,640 |
| GemtesaVibegron | 82 | $85,990 |
| MyrbetriqMirabegron | 86 | $85,872 |
| Tamsulosin Hcl | 686 | $9,413 |
| Finasteride | 435 | $4,944 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 154 | $2,900 |
| Testosterone Cypionate | 32 | $2,025 |
| Trospium Chloride | 36 | $1,624 |
| Methenamine Hippurate | 13 | $1,561 |
| Solifenacin Succinate | 28 | $1,321 |
| Dutasteride | 29 | $1,221 |
| Silodosin | 11 | $426 |
| Cefdinir | 24 | $389 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $217 |
| Sildenafil Citrate | 47 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,520 | $299,512102 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1,115 | $85,99082 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Isaac TunnellLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.